Hear From Pet Owners & Experts

Is your dog showing signs of OA pain?
Take the quiz to find out.

Take Quiz

What Veterinarians Are Saying

Librela empowers vets with an effective new tool to help control OA pain in dogs.

Librela Success Stories: Taffy & Norman

Taffy is a 9-year-old Golden Retriever who was having difficulties walking, getting up, and moving around due to OA pain. Once she started treatment with Librela, she got right back to doing the things she loves with the people she loves.
  • “It’s been 3 months [on Librela] and she is a different dog.”
Thanks to Librela, Taffy is back to long walks, traveling, and rolling in the sand.
Norman is a 6-year-old Cocker Spaniel mix who loves to be part of the action, but OA pain was holding him back. When he started treatment with Librela, he was back to his old self again, eager to explore and go on adventures.
  • “Once Norman started on Librela, he had much more of a pep in his step. He’s definitely able to go on those walks and have those adventures with me again.”
Since starting treatment with Librela, Norman is back to his hikes, running around, and, most importantly, sneaking treats from his favorite people.

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. Librela is for use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. Adverse events reported post-approval include ataxia (lack of balance/coordination), anorexia (loss of appetite), lethargy (tiredness), emesis (vomiting), and polydipsia (increased drinking). The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis (skin irritation/inflammation).

INDICATIONS: For the control of pain associated with osteoarthritis in dogs.

See the Client Information Sheet for more information about Librela.

References:

  1. ZMR: Canine Osteoarthritis Report Wave May 21, 2025. Zoetis Inc.
  2. Zoetis data on file. Zoetis. June 2026.
ZPC-02734R9

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient. 

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2026 Zoetis Services LLC. All rights reserved. ZPC-01562R2